Changes in U.S. Obesity Rates: Rapid Expansion of GLP-1 Drugs as a Possible Factor

The Light and Shadow of the GLP-1 Drug Boom Reflected in U.S. Data

In the U.S., signs of change are emerging in the obesity rate, which has been increasing almost unidirectionally for many years. The rapid spread of GLP-1 drugs, such as Ozempic, Wegovy, and Mounjaro, is believed to be a contributing factor.

An article reported by Gizmodo, based on a new data tracker released by Epic Research, highlights that the increase in GLP-1 prescriptions and the decrease in obesity rates are occurring simultaneously. The data shows that from the second quarter of 2021 to the first quarter of 2026, the number of GLP-1 prescriptions for U.S. adults increased significantly from about 1,900 to about 9,000 per 100,000 people. Meanwhile, the percentage of adults classified as "obese" by BMI decreased from 42.3% to 40.7%.

Looking at these numbers alone, one might be tempted to say, "Finally, drugs have reversed the trend of obesity." However, the situation is not that simple. Medical data is a snapshot of a part of society, and just because prescription increases and obesity rates decrease in parallel, it cannot be immediately concluded that GLP-1 drugs are the sole cause. Changes in diet, lifestyle changes post-COVID-19, increased health awareness, and changes in access to healthcare are all possible intertwined factors.

Nevertheless, the reason this data is attracting significant attention is clear. The obesity rate in the U.S. has long been a growing social and medical issue. According to CDC data, the adult obesity rate from August 2021 to August 2023 was 40.3%, with about 40% of U.S. adults classified as obese. In 2024 state data, at least one in four adults in all states and regions was at the obesity level. Therefore, even a slight decrease could have significant implications if it indicates a long-term trend reversal.

What Have GLP-1 Drugs Changed?

GLP-1 drugs were initially known as diabetes treatments, but their effects on appetite and satiety have gained attention, rapidly increasing their presence in the field of weight management. Drugs like Ozempic and Wegovy, with semaglutide as the active ingredient, and Mounjaro, with tirzepatide, are now discussed as representative options for obesity treatment.

Traditionally, obesity measures focused on "dietary restriction," "exercise," and "lifestyle improvement." Of course, these are still important. However, in reality, many people have not achieved sufficient results despite continued efforts, and cases of regaining weight after losing it were common. GLP-1 drugs have introduced a medical intervention option into this scenario.

Particularly noticeable on social media are voices from individuals saying, "For the first time, the battle with appetite has quieted." On platforms like Reddit, users of GLP-1 drugs have posted about realizing that they were not lazy but heavily influenced by their body's mechanisms. Many share experiences of reduced "food noise," where thoughts of food are constantly on their minds.

These reactions are challenging the societal view that has treated obesity as merely a matter of personal responsibility. There is a growing movement to reconsider weight management not as an issue of "willpower" but as a chronic health challenge involving hormones, metabolism, appetite control, social environment, and access to healthcare.

Voices on Social Media See It as a "Historic Turning Point"

On social media, there are many optimistic reactions to data like this. On Reddit, comments suggest that the peak of obesity rates in human history may have already passed, in light of the decrease in U.S. obesity rates and the spread of GLP-1 drugs. This is quite a bold perspective, but it symbolizes the high expectations for GLP-1 drugs.

In another discussion, some view GLP-1 drugs as a "revolutionary turning point in obesity treatment." Considering the burden of obesity-related diabetes, cardiovascular disease, sleep apnea, joint disorders, and more, a population-level weight reduction could significantly impact healthcare costs and quality of life. This perspective suggests that the drugs may have public health significance beyond individual cosmetic purposes.

However, caution is needed regarding the unique enthusiasm of social media. Personal stories are powerful, but individual differences are significant. A drug that works dramatically for one person may not be sustainable for another due to side effects. It is risky to view short-term success stories as evidence of a "magic drug" that works for everyone.

The Biggest Barrier: Cost and Insurance Coverage

In social media reactions to GLP-1 drugs, the issue of "cost" is as prominent as the expectations.

In a 2025 survey by KFF, about 12% of U.S. adults reported currently using GLP-1 drugs, and 18% had used them in the past. However, more than half of the users said that the cost was challenging. Even with partial insurance coverage, many face heavy out-of-pocket expenses, and without insurance, monthly payments can reach several hundred dollars.

On Reddit, there are heartfelt posts like, "The doctor says it's necessary, but who will pay for it?" People express concerns about whether to continue paying several hundred dollars monthly, despite being told by doctors that they could benefit from GLP-1 drugs for conditions like hypertension and sleep apnea, which are not covered by insurance.

This issue is crucial when considering the social impact of GLP-1 drugs. Even if the drugs can truly lower obesity rates and reduce related diseases, if access is limited to high-income individuals or those with favorable insurance conditions, health disparities could actually widen.

Obesity is a health challenge where the risk tends to be higher among low-income groups. Socioeconomic factors such as access to affordable and healthy food, a conducive environment for exercise, healthcare access, working hours, and stress have a significant impact. When an expensive drug enters the scene, a gap may emerge between those who can receive treatment and those left behind.

Concerns About Side Effects, Continuation, and Rebound

Cautious opinions about GLP-1 drugs are also strong on social media. Commonly cited are gastrointestinal symptoms like nausea, diarrhea, and constipation. The severity of side effects varies by person, but some discontinue use due to disruptions in daily life.

A larger issue is, "What happens if you stop?" GLP-1 drugs are not a cure for obesity that can be taken for a short period. While appetite is suppressed and weight decreases during use, appetite and weight may return after discontinuation. On social media, articles and personal stories about rebound after stopping the drugs are frequently shared, sparking debates about whether this is treatment or management assumed to continue for life.

In Reddit's weight loss community, there is anxiety about weight returning after stopping GLP-1 drugs. Even if weight is lost using the drugs, maintaining nutrition, muscle mass, exercise habits, sleep, and mental health becomes crucial. While drugs are a powerful tool, they do not single-handedly take over the design of one's entire lifestyle.

This point is important when considering the future of obesity treatment. As GLP-1 drugs become more widespread, medical professionals will need to make decisions not only about "starting" but also about "continuing," "how to maintain after weight loss," "how to adjust in case of side effects," and "who should be prioritized for use."

A Shift in the Value of "Is Obesity a Personal Responsibility?"

The significant social meaning of the current data lies not only in the numbers themselves. The spread of GLP-1 drugs is accelerating a change in values regarding obesity.

For a long time, obesity was discussed as a result of personal lack of effort, overeating, and lack of exercise. However, the fact that GLP-1 drugs significantly change appetite and satiety for some people has made it visible that weight is not determined solely by simple decision-making. On social media, many posts reflect the sentiment, "For the first time using this drug, I realized my body was sending signals different from the norm."

This has the potential to alleviate the stigma of obesity. If society moves towards treating weight issues as a treatable health challenge rather than a matter of shame or morality, more people may connect with healthcare.

On the other hand, new stigmas are also emerging. Views like "losing weight with drugs is cheating" or "taking the easy way out" are spreading. There is also a growing culture on social media of speculating whether celebrities have used Ozempic based on changes in their body shape. As GLP-1 drugs become more common, surveillance and prejudice regarding weight and drug use history may also intensify.

A Public Health Victory or Over-Medicalization?

While some see the spread of GLP-1 drugs as a "public health victory," others question whether it is merely an attempt to solve social problems with medication.

Indeed, the background of obesity includes many structural factors such as the food industry, ultra-processed foods, urban design, income inequality, work environment, lack of sleep, and stress. Even if GLP-1 drugs are effective, it does not mean these causes can be ignored. In fact, the introduction of drugs may risk delaying improvements in food environments and preventive policies.

However, the argument that "drugs are unnecessary because social environments should change" is also extreme. For those currently facing health risks, having more available treatment options is meaningful. Ideally, GLP-1 drugs should not be in opposition to diet, exercise, lifestyle support, and social policies but used in combination with them.

Discussions about obesity have often fallen into a dichotomy of "individual effort or social responsibility." In the era of GLP-1 drugs, what is needed is not to choose between the two. It is a multifaceted approach that does not blame individuals, ensures access to healthcare, improves living environments, and delivers effective treatments to those in need.

How Should We Interpret This Data?

The data from Epic Research shows very intriguing signals. As GLP-1 prescriptions increase, obesity rates decrease, and the percentage of adults within a healthy BMI range slightly increases. It is reported that among those with a history of GLP-1 prescriptions, the decrease in obesity rates is even greater.

However, this is not conclusive evidence that "GLP-1 drugs alone have started solving the U.S. obesity problem." There is a bias in the target population of electronic medical record data, and it is important to note that the data pertains to people visiting medical institutions. Additionally, while BMI is a convenient indicator, it does not adequately reflect muscle mass, body fat distribution, or metabolic state.

Still, in a country like the U.S., where obesity rates have remained high, the fact that multiple data points are beginning to show a downward trend is significant. If this trend continues over the next few years, GLP-1 drugs may be positioned as a major turning point in the history of obesity countermeasures, rather than just a fad.

Conclusion: Not a Magic Drug, But a Change That Cannot Be Ignored

GLP-1 drugs, including Ozempic, have significantly changed the discussion around obesity. The current data suggests the possibility of changes occurring at the population level, beyond individual weight loss success stories.

However, this is not a story of "solving everything with drugs." Issues such as cost, insurance coverage, side effects, the necessity of continuation, rebound, health disparities, and social prejudice remain. As social media reactions indicate, while people find hope in GLP-1 drugs, they also harbor strong concerns about their costs and inequities.

The important thing is not to overly idolize GLP-1 drugs. At the same time, the fact that people struggling with obesity have more effective options should not be overlooked. This is not a beauty trend but a significant public health theme encompassing chronic diseases, medical costs, social stigma, and health disparities.

Whether the decline in U.S. obesity rates is a temporary fluctuation or a genuine turning point is still unknown. But one thing is certain: the advent of GLP-1 drugs is bringing the era of dismissing obesity as "a lack of personal effort" to a close.

Source URL

Gizmodo. An article reporting on the relationship between the increase in GLP-1 prescriptions and the decrease in U.S. obesity rates, based on new data from Epic Research.
https://gizmodo.com/ozempic-is-finally-turning-the-tide-against-obesity-new-data-shows-2000763506

Epic official article. Explains the significant increase in GLP-1 prescriptions from the second quarter of 2021 to the first quarter of 2026, and the simultaneous decrease in obesity rates from 42.3% to 40.7%.
https://www.epic.com/epic/post/glp-1-prescriptions-quadruple-since-2021-alongside-decline-in-obesity/

CDC/NCHS Data Brief. Official statistics showing that the U.S. adult obesity rate was 40.3% from August 2021 to August 2023.
https://www.cdc.gov/nchs/products/databriefs/db508.htm

CDC Adult Obesity Rate Map. A document showing that as of 2024, at least one in four adults in all U.S. states and regions is obese, and regional obesity rates.
https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html

KFF 2025 GLP-1 Drug Usage Survey. Indicates that 12% of U.S. adults are currently using GLP-1 drugs, 18% have used them in the past, and highlights the difficulty of cost burden.
https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/

KFF 2024 GLP-1 Drug Usage Survey. Comparative data showing that as of 2024, 12% of adults have used GLP-1 drugs, and 6% are currently using them.
https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/

Reddit post. Referenced to understand the expectations and optimism on social media regarding the decline in U.S. obesity rates and the spread of GLP-1 drugs.
https://www.reddit.com/r/slatestarcodex/comments/1okdpli/since_2022_us_obesity_rate_down_3_use_of_glp1/

Reddit post. Referenced to understand the experiences, praise, skepticism, and reactions on social media regarding the cost and stigma of GLP-1 drugs.##HTML